Combivir and Ribavirin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Combivir (lamivudine; zidovudine) and Ribavirin (ribavirin). Common drug interactions include nausea among females and blood bilirubin increased among males.

The phase IV clinical study analyzes what interactions people have when they take Combivir and Ribavirin. It is created by eHealthMe based on reports of 67 people who take the same drugs from the FDA, and is updated regularly.

What is Combivir?

Combivir has active ingredients of lamivudine; zidovudine. It is often used in hiv infection. eHealthMe is studying from 15,450 Combivir users. Check the latest studies of Combivir.

What is Ribavirin?

Ribavirin has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 78,532 Ribavirin users. Check the latest studies of Ribavirin.



On Jul, 12, 2026

67 people who take Combivir and Ribavirin together, and have interactions are studied.

Combivir and Ribavirin drug interactions.

What are the common drug interactions of Combivir and Ribavirin, by gender? *:

female:

  1. Nausea (feeling of having an urge to vomit)
  2. Polydipsia (excessive thirst)
  3. Vision blurred
  4. Abdominal pain
  5. Abdominal pain upper
  6. Blood potassium decreased
  7. Cerebral disorder (brain disease)
  8. Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
  9. Decreased appetite
  10. Diarrhoea

male:

  1. Blood bilirubin increased
  2. Lipodystrophy acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired)
  3. Hepatosplenomegaly (enlargement of both the liver and the spleen)
  4. Retinal detachment (a disorder of the eye in which the retina peels away from its underlying layer of support tissue)
  5. Alanine aminotransferase increased
  6. Depression
  7. Dyspnoea (difficult or laboured respiration)
  8. Abdominal pain upper
  9. Anaemia (lack of blood)
  10. Aspartate aminotransferase increased

What are the common drug interactions of Combivir and Ribavirin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Abdominal pain upper
  2. Abnormal dreams
  3. Alanine aminotransferase increased
  4. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  5. Anxiety
  6. Aspartate aminotransferase increased
  7. Atrioventricular block (heart block)
  8. Atrioventricular block complete (heart block complete)
  9. Atrioventricular block second degree (heart block second degree)
  10. Balance disorder

30-39:

  1. Fatigue (feeling of tiredness)
  2. Thirst
  3. Weight decreased
  4. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
  5. Neuropathic pain (pain due to nerve inflammation and damage)
  6. Abdominal pain upper
  7. Diarrhoea
  8. Glycosylated haemoglobin increased
  9. Hepatic encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure)
  10. Hepatic failure (liver failure)

40-49:

  1. Thrombocytopenia (decrease of platelets in blood)
  2. Tinnitus (a ringing in the ears)
  3. Transaminases increased
  4. Ventricular extrasystoles (premature cardiac contraction)
  5. Vomiting
  6. Vulvar dysplasia (vulval dysplasia means that there are cells that are no longer normal and may be trying to become a cancer)
  7. White blood cell count increased
  8. Lipodystrophy acquired (a regional loss of subcutaneous adipose tissue which usually starts in the face, extends downward acquired)
  9. Hepatic steatosis (fatty liver disease)
  10. Lipohypertrophy (a lump under the skin caused by accumulation of extra fat at the site of many subcutaneous injections of insulin)

50-59:

  1. Malaise (a feeling of general discomfort or uneasiness)
  2. Platelet count decreased
  3. Alanine aminotransferase increased
  4. Aspartate aminotransferase increased
  5. Blood pressure increased
  6. Cough
  7. Depression
  8. Drug screen positive
  9. Dyspnoea (difficult or laboured respiration)
  10. Overdose

60+:

  1. Hyperglycaemia (high blood sugar)
  2. Appetite decreased (decreased appetite occurs when you have a reduced desire to eat)
  3. Dyspnoea exertional (breathlessness or shortness of breath)
  4. Fatigue (feeling of tiredness)
  5. Headache (pain in head)
  6. Homicidal ideation (thoughts about human killing another human)
  7. Pyrexia (fever)
  8. Suicidal ideation

What are the existing conditions these people have? *

  1. Hiv Infection: 28 people, 41.79%

* Approximation only. Some reports may have incomplete information.

Do you take Combivir and Ribavirin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Combivir and Ribavirin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Combivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ribavirin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Combivir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ribavirin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on lamivudine; zidovudine and ribavirin (the active ingredients of Combivir and Ribavirin, respectively), and Combivir and Ribavirin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: